KR101049868B1 - 신규한 인데노[2,1a]인덴 및 이소인돌[2,1-a]인돌 - Google Patents
신규한 인데노[2,1a]인덴 및 이소인돌[2,1-a]인돌 Download PDFInfo
- Publication number
- KR101049868B1 KR101049868B1 KR1020067012980A KR20067012980A KR101049868B1 KR 101049868 B1 KR101049868 B1 KR 101049868B1 KR 1020067012980 A KR1020067012980 A KR 1020067012980A KR 20067012980 A KR20067012980 A KR 20067012980A KR 101049868 B1 KR101049868 B1 KR 101049868B1
- Authority
- KR
- South Korea
- Prior art keywords
- indeno
- indene
- dioxide
- thia
- aza
- Prior art date
Links
- 0 *C(C1*)C2[C@@](C3*)N(*)[C@@]1C2C3c1c(-c2c(*3)c(*)c(*)c(*)c2*)[n]3c2c1c(*)c(*)c(*)c2* Chemical compound *C(C1*)C2[C@@](C3*)N(*)[C@@]1C2C3c1c(-c2c(*3)c(*)c(*)c(*)c2*)[n]3c2c1c(*)c(*)c(*)c2* 0.000 description 1
- HUFKRJSZPYMMOP-UHFFFAOYSA-N CN(CC1)CC1c(c1cc(OC2CCCC2)ccc11)c(-c2c3cccc2)[n]1S3(=O)=O Chemical compound CN(CC1)CC1c(c1cc(OC2CCCC2)ccc11)c(-c2c3cccc2)[n]1S3(=O)=O HUFKRJSZPYMMOP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
Description
Claims (15)
- 하기 화학식 1의 인데노[2,1a]인덴 및 이소인돌[2,1-a]인돌 유도체, 약제학적으로 허용 가능한 그의 염, 또는 그의 입체 이성질체:[화학식 1]상기 화학식 1에서,X는 -CH2-, -CO-, -S-, 또는 -S(O)1 또는 2, 이고;[ ---- ] 은 단일결합 또는 이중결합이고;R1, R2, R3, R4, R6, R7 , R8 및 R9 은 각각 독립적으로 수소, 할로겐, 퍼할로알킬, 퍼할로알콕시, 히드록시, (C1-C3)알킬, (C3-C5)시클로알킬, (C1-C3)알콕시, 시클로(C3-C5)알콕시, 아릴, 아릴옥시, 아랄킬, 아랄콕시, 헤테로시클릴, 모노알킬아미노, 디알킬아미노, 및 티오알킬을 나타내고;R11, R12, R13 및 R14는 각각 독립적으로 수소, 할로겐, 옥소, 티오, 퍼할로알킬, 퍼할로알콕시, 히드록시, 티올, 또는 (C1-C3)알킬을 나타낸다.
- 제 1 항에 있어서, 화합물 그룹에서 선택되는 것을 특징으로 하는 화합물 또는 약제학적으로 허용 가능한 그의 염:1. (R,S) 10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;2. (R,S) 10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;3. (R,S) 2-메톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴-5,5-디옥사이드;4. (R,S) 2-메톡시-10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;5. (R,S) 1-메톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;6. (R,S) 2-에톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;7. (R,S) 2-에톡시-10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;8. (R,S) 2-이소프로폭시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;9. (R,S) 1-이소프로폭시-10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;10. (R,S) 2-시클로펜틸옥시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;11. (R,S) 3-메톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;12. (R,S) 3-클로로-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;13. (R,S) 10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;14. (R,S) 2-메톡시-11-(1-메틸피롤리딘-3-일)-6H-이소인돌로[2,1-a]인돌;15. (S) 10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;16. (S) 10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;17. (S) 2-메톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴-5,5-디옥사이드;18. (S) 2-메톡시-10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a] 인덴 5,5-디옥사이드;19. (S) 1-메톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;20. (S) 2-에톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;21. (S) 2-에톡시-10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;22. (S) 2-이소프로폭시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;23. (S) 1-이소프로폭시-10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;24. (S) 2-시클로펜틸옥시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;25. (S) 3-메톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;26. (S) 3-클로로-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;27. (S) 10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;28. (S) 2-메톡시-11-(1-메틸피롤리딘-3-일)-6H-이소인돌로[2,1-a]인돌;29. (R) 10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;30. (R) 10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;31. (R) 2-메톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴-5,5-디옥사이드;32. (R) 2-메톡시-10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;33. (R) 1-메톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;34. (R) 2-에톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;35. (R) 2-에톡시-10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;36. (R) 2-이소프로폭시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;37. (R) 1-이소프로폭시-10-(1-에틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;38. (R) 2-시클로펜틸옥시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;39. (R) 3-메톡시-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;40. (R) 3-클로로-10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;41. (R) 10-(1-메틸피롤리딘-3-일)-5-티아-4b-아자-인데노[2,1-a]인덴 5,5-디옥사이드;42. (R) 2-메톡시-11-(1-메틸피롤리딘-3-일)-6H-이소인돌로[2,1-a]인돌.
- 하기 화학식 2의 화합물을 촉매로서 Pd(O) 또는 Pd(Ⅱ) 유도체를 이용하여 고리화하는 단계를 포함하는, 제 1항에 따른 화학식 1의 화합물의 제조방법:[화학식 2]상기 화학식 2에서,X는 -CH2-, -CO-, -S-, 또는 -S(O)1 또는 2 이고;[ ---- ] 은 단일결합 또는 이중결합이고;R1, R2, R3, R4, R6, R7 , R8 및 R9 은 각각 독립적으로 수소, 할로겐, 퍼할로알킬, 퍼할로알콕시, 히드록시, (C1-C3)알킬, (C3-C5)시클로알킬, (C1-C3)알콕시, 시클로(C3-C5)알콕시, 아릴, 아릴옥시, 아랄킬, 아랄콕시, 헤테로시클릴, 모노알킬아미노, 디알킬아미노, 및 티오알킬을 나타내고;R11, R12, R13 및 R14는 각각 독립적으로 수소, 할로겐, 옥소, 티오, 퍼할로알킬, 퍼할로알콕시, 히드록시, 티올, 또는 (C1-C3)알킬을 나타내고;R5 또는 R10 그룹 중 어느 하나는 브로모, 클로로, 또는 요오도 같은 할로겐 원자이고, 다른 하나는 수소이다.
- 제 3 항에 있어서, 화학식 1의 유용한 화합물을 획득하기 위해화학식 1의 라세믹 화합물을 순수한 광학적으로 활성인 형태로 전환시키는 단계; 또는화학식 1의 한 화합물을 화학식 1의 또 다른 화합물로 전환시키는 단계; 또는임의의 보호기를 제거하는 단계; 또는화학식 1의 화합물의 약제학적으로 허용 가능한 염 또는 프로드럭을 형성시키는 단계를 더 포함하는 것을 특징으로 하는 방법.
- 제 3 항 또는 제 4 항에 있어서, 상기 Pd(O) 또는 Pd(Ⅱ) 유도체는 테트라키스 트리페닐포스핀 팔라듐, (비스-트리-o-톨릴포스핀)팔라듐로부터 선택되며, 상기 고리화는 염기의 존재 하에서 수행하는 것을 특징으로 하는 방법.
- 제 3 항 또는 제 4 항에 있어서, 상기 고리화는 염기의 존재 하에서 수행하는 것을 특징으로 하는 방법.
- 약제학적으로 허용 가능한 부형제 이외에 제 2 항에 따른 하나 이상의 화합물 또는 약제학적으로 허용 가능한 그의 염 중 하나를 함유하는 CNS 질환, 섭식 장애, 위장관 질환, 혈액학적 질환, 통증 질환, 호흡기 질환, 비뇨생식기 질환, 심혈관계 질환, 또는 암의 치료 또는 예방을 위한 약제학적 조성물.
- 삭제
- 제 7 항에 있어서, 상기 CNS 질환은 정신병, 망상분열증, 불안증, 우울증, 조증, 정신분열증, 정신분열형 장애, 편두통, 약물 중독, 경련성 장애, 인격 장애, 고혈압, 자폐증, 외상후 스트레스 증후군, 알콜 중독, 공황 발작, 강박반응성 장애, 시간생물학적 이상 하루주기 리듬(chronobiological abnormalities and circadian rhythms), 인지 기억 장애, ADHD(집중력 결핍 장애/ 과활동성 증후군), 근위축성 측삭경화증, 약물 중독의 금단 증후군, 공황 발작, 또는 척수 외상 또는 머리 이상, 약한 인지 손상, 또는 신경퇴행성 질환과 관련된 장애인 것을 특징으로 하는 약제학적 조성물.
- 제 7 항에 있어서, 상기 위장관 질환은 IBS(과민성 대장 증후군) 또는 화학요법에 인한 구토증인 것을 특징으로 하는 약제학적 조성물.
- 제 7 항에 있어서, 섭식장애의 조절을 위한 것을 특징으로 하는 약제학적 조성물.
- 삭제
- 삭제
- 삭제
- 제 2 항에 정의된 화합물을 이용하여, 인간을 제외한 포유류의 CNS 질환, 섭식 장애, 위장관 장애, 혈액학적 장애, 통증 질환, 호흡기 장애, 비뇨생식기 장애, 심혈관계 질환, 또는 암을 예방 또는 치료하는 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN5CH2004 | 2004-01-02 | ||
IN5/CHE/2004 | 2004-01-02 | ||
PCT/IN2004/000430 WO2005066184A1 (en) | 2004-01-02 | 2004-12-30 | Novel indeno[2,1a]indenes and isoindol[2,1-a]indoles |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070008541A KR20070008541A (ko) | 2007-01-17 |
KR101049868B1 true KR101049868B1 (ko) | 2011-07-19 |
Family
ID=34746651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067012980A KR101049868B1 (ko) | 2004-01-02 | 2004-12-30 | 신규한 인데노[2,1a]인덴 및 이소인돌[2,1-a]인돌 |
Country Status (25)
Country | Link |
---|---|
US (1) | US7388024B2 (ko) |
EP (1) | EP1704154B1 (ko) |
JP (1) | JP4886522B2 (ko) |
KR (1) | KR101049868B1 (ko) |
CN (1) | CN1918173B (ko) |
AT (1) | ATE430752T1 (ko) |
AU (1) | AU2004312229B2 (ko) |
BR (1) | BRPI0417895B8 (ko) |
CA (1) | CA2552106C (ko) |
CY (1) | CY1109278T1 (ko) |
DE (1) | DE602004021031D1 (ko) |
DK (1) | DK1704154T3 (ko) |
EA (1) | EA010406B1 (ko) |
ES (1) | ES2326658T3 (ko) |
HK (1) | HK1097548A1 (ko) |
HR (1) | HRP20090419T1 (ko) |
MX (1) | MXPA06007415A (ko) |
NO (1) | NO335838B1 (ko) |
NZ (1) | NZ548743A (ko) |
PL (1) | PL1704154T3 (ko) |
PT (1) | PT1704154E (ko) |
RS (1) | RS50824B (ko) |
SI (1) | SI1704154T1 (ko) |
WO (1) | WO2005066184A1 (ko) |
ZA (1) | ZA200604748B (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102482292B (zh) * | 2009-04-23 | 2017-07-18 | Abbvie 公司 | 5‑ht受体的调节剂和其使用方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003035061A1 (en) | 2001-10-23 | 2003-05-01 | Biovitrum Ab | Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake |
WO2004000845A1 (en) | 2002-06-21 | 2003-12-31 | Suven Life Sciences Limited | Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994352A (en) * | 1998-11-13 | 1999-11-30 | Pfizer Inc. | 5-arylindole derivatives |
CN1281605C (zh) * | 2000-12-22 | 2006-10-25 | 惠氏公司 | 作为5-羟色胺-6配基的杂环基-吲唑或氮杂吲唑化合物 |
EP1377580B1 (en) * | 2001-01-30 | 2006-09-27 | Eli Lilly And Company | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor |
ES2187300B1 (es) * | 2001-11-14 | 2004-06-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. |
ATE335477T1 (de) * | 2001-12-20 | 2006-09-15 | Wyeth Corp | Indolylalkylamin-derivate als 5-hydroxytryptamin- 6 liganden |
EP1472544A2 (en) | 2002-02-01 | 2004-11-03 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
WO2003066056A1 (en) | 2002-02-05 | 2003-08-14 | Glaxo Group Limited | Method of promoting neuronal growth |
WO2004000205A2 (en) * | 2002-06-21 | 2003-12-31 | Suven Life Sciences Limited | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
EP1523486B1 (en) * | 2002-06-21 | 2007-11-07 | Suven Life Sciences Limited | Tetracyclic arylsulfonyl indoles having serotonin receptor affinity |
AU2003285759B2 (en) | 2002-11-28 | 2010-01-28 | Suven Life Sciences Limited | N-arylsulfonyl-3-aminoalkoxyindoles |
WO2004048331A1 (en) | 2002-11-28 | 2004-06-10 | Suven Life Sciences Limited | N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands |
KR100818508B1 (ko) | 2002-11-28 | 2008-03-31 | 수벤 라이프 사이언시스 리미티드 | 세로토닌 수용체 친화력을 가지는 엔-아릴술포닐-3-치환인돌, 그 제조방법 및 그를 포함하는 약제학적 조성물 |
PT1581538E (pt) | 2002-12-18 | 2007-05-31 | Suven Life Sciences Ltd | Indolos tetracíclicos substituidos na posição 3 que possuem afinidade pelo receptor de serotonina. |
-
2004
- 2004-12-30 JP JP2006546485A patent/JP4886522B2/ja not_active Expired - Fee Related
- 2004-12-30 CA CA2552106A patent/CA2552106C/en not_active Expired - Fee Related
- 2004-12-30 PL PL04806777T patent/PL1704154T3/pl unknown
- 2004-12-30 BR BRPI0417895A patent/BRPI0417895B8/pt not_active IP Right Cessation
- 2004-12-30 RS RSP-2009/0329A patent/RS50824B/sr unknown
- 2004-12-30 SI SI200431175T patent/SI1704154T1/sl unknown
- 2004-12-30 DK DK04806777T patent/DK1704154T3/da active
- 2004-12-30 PT PT04806777T patent/PT1704154E/pt unknown
- 2004-12-30 ES ES04806777T patent/ES2326658T3/es active Active
- 2004-12-30 KR KR1020067012980A patent/KR101049868B1/ko active IP Right Grant
- 2004-12-30 AU AU2004312229A patent/AU2004312229B2/en not_active Ceased
- 2004-12-30 EP EP04806777A patent/EP1704154B1/en active Active
- 2004-12-30 WO PCT/IN2004/000430 patent/WO2005066184A1/en active Application Filing
- 2004-12-30 CN CN2004800417654A patent/CN1918173B/zh not_active Expired - Fee Related
- 2004-12-30 MX MXPA06007415A patent/MXPA06007415A/es active IP Right Grant
- 2004-12-30 DE DE602004021031T patent/DE602004021031D1/de active Active
- 2004-12-30 NZ NZ548743A patent/NZ548743A/xx not_active IP Right Cessation
- 2004-12-30 AT AT04806777T patent/ATE430752T1/de active
- 2004-12-30 EA EA200601270A patent/EA010406B1/ru not_active IP Right Cessation
-
2006
- 2006-06-09 ZA ZA200604748A patent/ZA200604748B/xx unknown
- 2006-06-15 NO NO20062805A patent/NO335838B1/no not_active IP Right Cessation
- 2006-06-29 US US11/478,968 patent/US7388024B2/en active Active
-
2007
- 2007-05-14 HK HK07105039.5A patent/HK1097548A1/xx not_active IP Right Cessation
-
2009
- 2009-07-29 HR HR20090419T patent/HRP20090419T1/hr unknown
- 2009-08-03 CY CY20091100812T patent/CY1109278T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003035061A1 (en) | 2001-10-23 | 2003-05-01 | Biovitrum Ab | Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake |
WO2004000845A1 (en) | 2002-06-21 | 2003-12-31 | Suven Life Sciences Limited | Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8569288B2 (en) | Thienotriazolodiazepine derivatives active on apo A | |
WO2005066157A1 (en) | 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators | |
US20220017514A1 (en) | Heterocyclic compound | |
AU2003292510B2 (en) | Tetracyclic 3-substituted indoles having serotonin receptor affinity | |
MXPA05005700A (es) | N-arilsulfonil-3-aminoalcoxiindoles. | |
WO2007046112A1 (en) | Arylthioether tryptamine derivatives as functional 5-ht6 ligands | |
RO112505B1 (ro) | DERIVATI DE 1, 2, 3-4-TETRAHIDROCICLOPENT (b) INDOLI, SI 1, 2, 3, 3a, 4, 8a - HEXAHIDROCICLOPENT (b) INDOLI SUBSTITUITI | |
JP2005522408A (ja) | 5−HT受容体リガントとしてのヘキサヒドロアゼピノ(4,5−g)インドールおよびインドリン | |
KR101049868B1 (ko) | 신규한 인데노[2,1a]인덴 및 이소인돌[2,1-a]인돌 | |
WO2020196828A1 (ja) | 含窒素複素環化合物 | |
AU2003249582A1 (en) | Tetracyclic arylsulfonyl indoles having serotonin receptor affinity | |
EP1948166B1 (en) | Carbazole derivatives as functional 5-ht6 ligands | |
WO2007138611A1 (en) | 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands | |
AU2009294181B2 (en) | Aryl sulfonamide amine compounds and their use as 5-HT6 ligands | |
WO2001014385A1 (fr) | Derives de dihydrobenzofuran, leur procede de preparation et agents | |
JP6347830B2 (ja) | ピラジノ[1,2−a]インドール化合物、その調製および医薬としての使用 | |
JPH10508873A (ja) | 光学分割によるキラルな5−アミノカルボニル−5H−ジベンゾ[a, d]シクロヘプテン−5,10−イミンの製造 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140611 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150513 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160318 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170320 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180620 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190412 Year of fee payment: 9 |